(3R,4S,5R,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(2R,3R,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Term ID

CHEBI:152178

Synonyms

D-galacto-hexopyranosyl-(1->3)-D-galacto-hexopyranosyl-(1->3)-D-galacto-hexopyranosyl-(1->3)-D-galacto-hexopyranosyl-(1->3)-D-galacto-hexopyranosyl-(1->3)-D-galacto-hexopyranosyl-(1->4)-D-galacto-hexopyranosyl-(1->4)-D-gluco-hexopyranose
Gal(?1-3)Gal(?1-3)Gal(?1-3)Gal(?1-3)Gal(?1-3)Gal(?1-4)Gal(?1-4)Glc
WURCS=2.0/2,8,7/[a2122h-1x_1-5][a2112h-1x_1-5]/1-2-2-2-2-2-2-2/a4-b1_b4-c1_c3-d1_d3-e1_e3-f1_f3-g1_g3-h1

Definition

References

GlyGen:G60539QY
GlyTouCan:G60539QY

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (3R,4S,5R,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(2R,3R,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype where environments contain (3R,4S,5R,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(2R,3R,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype modified by environments containing (3R,4S,5R,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(2R,3R,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Phenotype affecting (3R,4S,5R,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(3R,4S,5S,6R)-2-[(2R,3R,4R,5R)-4,5-Dihydroxy-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol

Human Disease Model